Renalytix (RENX) Competitors

GBX 1.71 +0.11 (+6.54%)

As of 11:41 AM Eastern

RENX vs. COG, INHC, FDBK, IQAI, and DVRG

Should you buy Renalytix stock or one of its competitors? MarketBeat compares Renalytix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Renalytix include Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), and DeepVerge (DVRG). These companies are all part of the "health information services" industry.

How does Renalytix compare to Cambridge Cognition?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

14.0% of Renalytix shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 5.1% of Renalytix shares are owned by company insiders. Comparatively, 3.4% of Cambridge Cognition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 60.00%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cambridge Cognition has a net margin of -17.82% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-680.00%	274.67%	-93.54%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

In the previous week, Cambridge Cognition had 1 more articles in the media than Renalytix. MarketBeat recorded 2 mentions for Cambridge Cognition and 1 mentions for Renalytix. Cambridge Cognition's average media sentiment score of 0.00 beat Renalytix's score of -1.02 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Renalytix	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Cambridge Cognition	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Renalytix has a beta of 1.974, indicating that its share price is 97% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.832, indicating that its share price is 17% less volatile than the broader market.

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	2.26	-£109.93M	-£4.00	N/A
Cambridge Cognition	£9.40M	1.73	-£1.58M	-£3.90	N/A

Summary

Cambridge Cognition beats Renalytix on 11 of the 16 factors compared between the two stocks.

How does Renalytix compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Induction Healthcare Group has a net margin of -23.86% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Induction Healthcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Induction Healthcare Group	-23.86%	-14.58%	-7.32%
Renalytix	-680.00%	274.67%	-93.54%

In the previous week, Renalytix had 1 more articles in the media than Induction Healthcare Group. MarketBeat recorded 1 mentions for Renalytix and 0 mentions for Induction Healthcare Group. Induction Healthcare Group's average media sentiment score of 0.00 beat Renalytix's score of -1.02 indicating that Induction Healthcare Group is being referred to more favorably in the media.

Company	Overall Sentiment
Induction Healthcare Group	Neutral
Renalytix	Negative

Induction Healthcare Group has higher revenue and earnings than Renalytix. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A
Renalytix	£3.30M	2.26	-£109.93M	-£4.00	N/A

Induction Healthcare Group has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.974, meaning that its share price is 97% more volatile than the broader market.

46.3% of Induction Healthcare Group shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 54.6% of Induction Healthcare Group shares are owned by insiders. Comparatively, 5.1% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Induction Healthcare Group beats Renalytix on 7 of the 13 factors compared between the two stocks.

How does Renalytix compare to Feedback?

Feedback (LON:FDBK) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

35.7% of Feedback shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 8.0% of Feedback shares are owned by company insiders. Comparatively, 5.1% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Feedback and Feedback both had 1 articles in the media. Feedback's average media sentiment score of 0.75 beat Renalytix's score of -1.02 indicating that Feedback is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Feedback	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Renalytix	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Renalytix has a net margin of -680.00% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 274.67% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Feedback	-845.25%	-135.17%	-22.99%
Renalytix	-680.00%	274.67%	-93.54%

Feedback has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.974, suggesting that its stock price is 97% more volatile than the broader market.

Feedback has higher earnings, but lower revenue than Renalytix. Feedback is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Feedback	£849.62K	4.54	-£10.84M	-£15.74	N/A
Renalytix	£3.30M	2.26	-£109.93M	-£4.00	N/A

Summary

Feedback and Renalytix tied by winning 6 of the 12 factors compared between the two stocks.

How does Renalytix compare to IQ-AI?

Renalytix (LON:RENX) and IQ-AI (LON:IQAI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Renalytix had 1 more articles in the media than IQ-AI. MarketBeat recorded 1 mentions for Renalytix and 0 mentions for IQ-AI. IQ-AI's average media sentiment score of 0.00 beat Renalytix's score of -1.02 indicating that IQ-AI is being referred to more favorably in the news media.

Company	Overall Sentiment
Renalytix	Negative
IQ-AI	Neutral

IQ-AI has a net margin of -77.52% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat IQ-AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-680.00%	274.67%	-93.54%
IQ-AI	-77.52%	-140.75%	-22.03%

Renalytix has a beta of 1.974, suggesting that its stock price is 97% more volatile than the broader market. Comparatively, IQ-AI has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market.

IQ-AI has lower revenue, but higher earnings than Renalytix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	2.26	-£109.93M	-£4.00	N/A
IQ-AI	£538.19K	3.30	N/A	N/A	N/A

14.0% of Renalytix shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 66.0% of IQ-AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

IQ-AI beats Renalytix on 6 of the 11 factors compared between the two stocks.

How does Renalytix compare to DeepVerge?

Renalytix (LON:RENX) and DeepVerge (LON:DVRG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Renalytix has a beta of 1.974, indicating that its share price is 97% more volatile than the broader market. Comparatively, DeepVerge has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

DeepVerge has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	2.26	-£109.93M	-£4.00	N/A
DeepVerge	£12.41M	0.00	-£2.46M	-£0.01	N/A

In the previous week, Renalytix had 1 more articles in the media than DeepVerge. MarketBeat recorded 1 mentions for Renalytix and 0 mentions for DeepVerge. DeepVerge's average media sentiment score of 0.00 beat Renalytix's score of -1.02 indicating that DeepVerge is being referred to more favorably in the news media.

Company	Overall Sentiment
Renalytix	Negative
DeepVerge	Neutral

DeepVerge has a net margin of -19.81% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat DeepVerge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-680.00%	274.67%	-93.54%
DeepVerge	-19.81%	-10.27%	-5.56%

14.0% of Renalytix shares are held by institutional investors. Comparatively, 4.2% of DeepVerge shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 9.5% of DeepVerge shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

DeepVerge beats Renalytix on 7 of the 12 factors compared between the two stocks.

Get Renalytix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RENX vs. The Competition

Export

Metric	Renalytix	Health Information Services Industry	Medical Sector	LON Exchange
Market Cap	£7.47M	£288.17M	£6.23B	£2.76B
Dividend Yield	N/A	5.60%	2.81%	6.15%
P/E Ratio	-0.43	176.28	20.55	365.83
Price / Sales	2.26	123.07	547.77	88,116.31
Price / Cash	1.84	47.14	27.48	27.89
Price / Book	-0.16	5.24	9.71	7.65
Net Income	-£109.93M	-£22.78M	£3.56B	£5.89B
7 Day Performance	6.54%	-2.03%	-1.77%	-0.17%
1 Month Performance	-14.50%	-4.77%	-2.53%	0.55%
1 Year Performance	-79.88%	-12.74%	31.63%	85.05%

Renalytix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RENX Renalytix	N/A	GBX 1.71 +6.5%	N/A	-81.1%	£7.47M	£3.30M	N/A	102	Gap Down
COG Cambridge Cognition	1.1715 of 5 stars	GBX 35 flat	GBX 56 +60.0%	-10.3%	£16.29M	£9.40M	N/A	80	High Trading Volume
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+2.6%	£9.00M	£12.57M	N/A	74
FDBK Feedback	N/A	GBX 9 -1.1%	N/A	-33.6%	£3.94M	£849.62K	N/A	24
IQAI IQ-AI	N/A	GBX 0.80 flat	N/A	-3.0%	£1.77M	£538.19K	N/A	6	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:RENX) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Renalytix (RENX) Competitors

RENX vs. COG, INHC, FDBK, IQAI, and DVRG

How does Renalytix compare to Cambridge Cognition?

Summary

How does Renalytix compare to Induction Healthcare Group?

Summary

How does Renalytix compare to Feedback?

Summary

How does Renalytix compare to IQ-AI?

Summary

How does Renalytix compare to DeepVerge?

Summary

Media Sentiment Over Time

RENX vs. The Competition

Renalytix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Renalytix (RENX) Competitors

RENX vs. COG, INHC, FDBK, IQAI, and DVRG

How does Renalytix compare to Cambridge Cognition?

Do institutionals & insiders believe in RENX or COG?

Do analysts prefer RENX or COG?

Is RENX or COG more profitable?

Does the media refer more to RENX or COG?

Which has more volatility & risk, RENX or COG?

Which has preferable earnings & valuation, RENX or COG?

Summary

How does Renalytix compare to Induction Healthcare Group?

Is INHC or RENX more profitable?

Does the media favor INHC or RENX?

Which has higher earnings and valuation, INHC or RENX?

Which has more risk & volatility, INHC or RENX?

Do insiders & institutionals believe in INHC or RENX?

Summary

How does Renalytix compare to Feedback?

Do institutionals & insiders believe in FDBK or RENX?

Does the media refer more to FDBK or RENX?

Is FDBK or RENX more profitable?

Which has more risk & volatility, FDBK or RENX?

Which has stronger valuation & earnings, FDBK or RENX?

Summary

How does Renalytix compare to IQ-AI?

Does the media refer more to RENX or IQAI?

Is RENX or IQAI more profitable?

Which has more risk & volatility, RENX or IQAI?

Which has higher earnings and valuation, RENX or IQAI?

Do institutionals & insiders have more ownership in RENX or IQAI?

Summary

How does Renalytix compare to DeepVerge?

Which has more volatility & risk, RENX or DVRG?

Which has preferable earnings & valuation, RENX or DVRG?

Does the media refer more to RENX or DVRG?

Is RENX or DVRG more profitable?

Do institutionals and insiders hold more shares of RENX or DVRG?

Summary

Media Sentiment Over Time

RENX vs. The Competition

Renalytix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools